MALIGNANT RHABDOID TUMOR
Clinical trials for MALIGNANT RHABDOID TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT RHABDOID TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT RHABDOID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on childhood cancers in early trial
Disease control OngoingThis study tests a new treatment called AGAR T cells for children whose solid tumors (like liver cancer or Wilms tumor) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding genes to help them recognize and attack tumo…
Matched conditions: MALIGNANT RHABDOID TUMOR
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Promising drug targets rare childhood brain and kidney tumors
Disease control OngoingThis study tests a drug called alisertib in children and young adults under 22 with rare, aggressive tumors of the brain (AT/RT) or kidney (MRT). For those whose cancer has returned or not responded, alisertib is given alone. For newly diagnosed patients, it is combined with chem…
Matched conditions: MALIGNANT RHABDOID TUMOR
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered t cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new treatment called CATCH T cells for people with certain solid tumors that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells, adding new genes to help them recognize and attack cancer cell…
Matched conditions: MALIGNANT RHABDOID TUMOR
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Immunotherapy duo takes on rare childhood tumors
Disease control OngoingThis study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have returned or not responded to standard treatments. The goal is to see if the drug combo helps the…
Matched conditions: MALIGNANT RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC